Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 362 | 0.71 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6080
Sealed predictions
- SLC2A9 in dopamine neurons, braak-0.71 (p 0.032) → -0.02 (p 0.964)receipt 6087
Swarm cases
receipt 6087: SLC2A9 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.269, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.341, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.047, n 18). not the mix.
- skeptic
- leave-one-out range -0.41 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.269, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC2A9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts